Increasing Prevalence of Hormone-Responsive Cancers
Across Africa, the prevalence of hormone-responsive cancers is rising as demographic shifts, urbanization, and lifestyle changes intersect with improving diagnostic awareness. Breast cancer is now the most commonly diagnosed cancer among women in many countries, including South Africa, Nigeria, Kenya, and Morocco, with a significant proportion being hormone receptor–positive. Prostate cancer incidence is increasing across Sub-Saharan Africa, particularly in Southern and West Africa, driven by population aging and greater use of PSA testing in urban centers. Although overall incidence rates remain lower than in Western regions, late presentation and growing survivor populations are expanding the need for sustained hormone therapy.
Epidemiologic transitions are amplifying risk factors relevant to endocrine-driven malignancies. Rising obesity rates, reduced physical activity, and dietary changes are linked to estrogen-mediated breast cancer risk in urban populations, while longer life expectancy increases cumulative prostate cancer burden. In North Africa, countries such as Egypt and Tunisia report growing breast cancer prevalence with improving pathology services enabling hormone receptor testing. As more tumors are accurately classified, eligibility for endocrine therapy is increasing, expanding the addressable patient base for hormone treatments.
Health system constraints shape how hormone therapy demand materializes. In African settings, limited radiotherapy and chemotherapy capacity elevate the importance of oral hormone therapies as accessible, relatively affordable treatment options. Public sector oncology services in South Africa and selected North African countries use tamoxifen, aromatase inhibitors, and androgen-deprivation therapies as backbone treatments. As national cancer control plans prioritize essential medicines lists and early detection, hormone therapy continues to become a cornerstone of cancer management across diverse resource settings.
Rising Adoption of Combination Regimens
Combination regimens involving hormone therapy are emerging gradually across Africa, with adoption strongly correlated to health system capacity and reimbursement structures. In middle-income markets such as South Africa, Egypt, and Algeria, endocrine therapies are combined with targeted agents for hormone receptor–positive breast cancer, particularly in private-sector and academic hospitals. While access to CDK4/6 inhibitors and newer androgen receptor inhibitors remains uneven, their inclusion in treatment guidelines signals a shift toward more comprehensive regimens where feasible.
In prostate cancer, androgen-deprivation therapy remains the foundation of care, with limited but growing use of combination approaches in metastatic disease. South Africa leads the region in incorporating next-generation hormonal agents alongside ADT, while pilot programs and donor-supported initiatives in East and West Africa are expanding access to improved systemic therapies. Even where advanced agents are unavailable, sequential use of different hormone therapies reflects an incremental move toward more sophisticated treatment strategies.
Policy reforms and international partnerships are key enablers of combination therapy uptake. WHO essential medicines guidance, pooled procurement mechanisms, and NGO-supported access programs are improving the availability of traditional and newer endocrine agents. Training collaborations and regional oncology networks are also strengthening clinician familiarity with combination protocols. As infrastructure, reimbursement, and diagnostic capacity improve, Africa’s market is expected to evolve from monotherapy-dominant use toward broader adoption of combination regimens, anchored by hormone therapy as the treatment backbone.
